A PHASE II RANDOMIZED NON COMPARATIVE STUDY ON THE ACTIVITY OF TRABECTEDIN OR GEMCITABINE + DOCETAXEL IN METASTATIC OR LOCALLY RELAPSED UTERINE LEIOMYOSARCOMA PRETREATED WITH CONVENTIONAL CHEMOTHERAPY

Trial Profile

A PHASE II RANDOMIZED NON COMPARATIVE STUDY ON THE ACTIVITY OF TRABECTEDIN OR GEMCITABINE + DOCETAXEL IN METASTATIC OR LOCALLY RELAPSED UTERINE LEIOMYOSARCOMA PRETREATED WITH CONVENTIONAL CHEMOTHERAPY

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2017

At a glance

  • Drugs Trabectedin (Primary) ; Docetaxel; Gemcitabine
  • Indications Uterine leiomyoma
  • Focus Therapeutic Use
  • Acronyms TAUL
  • Most Recent Events

    • 05 Dec 2017 Status changed from active, no longer recruiting to completed.
    • 21 Mar 2017 Planned primary completion date changed from 1 Sep 2016 to 1 Jul 2017.
    • 10 Nov 2016 According to a PharmaMar media release, data from this trial will be presented at the 21st Annual Meeting of the Connective Tissue Oncology Society (CTOS).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top